Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Go back to Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
(NASDAQ: BMEA) Delayed: 0.69 --0 (-0%)
Previous Close $0.69    52 Week High $ 
Open $0.69    52 Week Low $ 
Day High $0.69    P/E N/A 
Day Low $0.69    EPS $ 
Volume 4,694